Straits Times Index
3,322.62 +14.72 (+0.45%) S&P 500
5,267.56 -39.45 (-0.74%) Dow
39,069.84 -601.20 (-1.52%) Nasdaq
16,730.75 -70.79 (-0.42%) Bitcoin USD
67,548.09 -2,132.60 (-3.06%) CMC Crypto 200
1,458.58 -44.09 (-2.93%)
AMGN Jul 2024 280.000 call
| Previous close | 41.33 |
| Open | 38.45 |
| Bid | 29.75 |
| Ask | 31.10 |
| Strike | 280.00 |
| Expiry date | 2024-07-19 |
| Day's range | 38.31 - 41.89 |
| Contract range | N/A |
| Volume | |
| Open interest | 877 |
ZacksTop Stock Reports for Apple, Mastercard & Amgen
Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), Mastercard (MA) and Amgen (AMGN), as well as two micro-cap stocks Utah Medical Products, Inc. (UTMD) and Bridger Aerospace Group Holdings, Inc. (BAER).
BenzingaAmgen/AstraZeneca Say Asthma Drug Shows Activity In Another Lung Disease Across Broad Patient Population
Sunday, Amgen Inc (NASDAQ:AMGN) and AstraZeneca Plc (NASDAQ:AZN) announced the results of the Phase 2a COURSE trial of Tezspire (tezepelumab-ekko) for severe chronic obstructive pulmonary disease (COPD) with a broad range of baseline blood eosinophil counts (BEC) irrespective of emphysema, chronic bronchitis or smoking status. The primary results showed that treatment with Tezspire led to a 17% numerical reduction in the annual rate of moderate or severe COPD exacerbations compared to placebo at
ZacksThe Zacks Analyst Blog Highlights Stocks recently featured in the blog include: Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen
Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen are included in this Analyst Blog.
